CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 250 target
Drug / intervention
Carbon ions therapy +1 moreradiation
Likely dose
Not stated in record
Key inclusion· 16
  • Age 18 years or older
  • Unresectable, inoperable, or R2 resection of tumor
  • Adenoid cystic carcinoma of head and neck (excluding larynx and trachea)
  • Soft tissue sarcoma
Key exclusion· 10
  • Complete macroscopic or microscopic surgical resection (R0 or R1)
  • Prior irradiation in the treatment volume
  • Metastatic disease
  • Disease not candidate for curative approach

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02838602
NCT02838602N/ARecruitingOn TrackUpdated 57mo ago
Long Recruiting

Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors

Hospices Civils de Lyon·interventional·Posted Jul 20, 2016·Updated Sep 2, 2021

In Brief

A clinical study evaluating Carbon ions therapy and Advanced external radiotherapy by Xrays or protons for Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma. Currently recruiting, targeting 250 participants across 21 sites.

Detailed Summary

This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ARecruiting
20172018201920202021202220232024202520262027
First PostedJul 20, 2016
Enrollment StartDec 23, 2017
Primary CompletionDec 23, 2026
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 10.0 years agoPrimary completion in 6 months

Interventions

Carbon ions therapyradiation

External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center

Advanced external radiotherapy by Xrays or protonsradiation

Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy